Ipsen grants Rhythm licence to non-core metabolic programmes
15 March 2010
Sukaina Virji
sukaina.virji@informa.com
Ipsen has granted Rhythm Pharmaceuticals an exclusive worldwide licence for the development and commercialisation of its melanocortin and ghrelin programmes.
The early preclinical peptide compounds in the programmes target obesity, metabolic diseases and gastrointestinal disorders.
Ipsen...
Please Login to read the full article.